In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
The plant is expected to start commercial operations from Q4FY24
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
University of Pennsylvania scientists Katalin Karikó and Drew Weissman to be honoured at June 7 symposium in New York City for their research that enabled Covid-19 vaccines
Subscribe To Our Newsletter & Stay Updated
